Month: August 2022

Revenue and Adjusted EBITDA Revenue and Adjusted EBITDAAdjusted Net Earnings and Free Cash Flow TTM Adjusted Net Earnings and Free Cash Flow TTMSugar Volume Variance and Sugar Volumes Sugar Volume Variance and Sugar VolumesSugar Volume Variance and Sugar Volumes Sugar Volume Variance and Sugar VolumesAdjusted Gross Margin Adjusted Gross MarginMaple Volumes and Adjusted Gross Margin Maple Volumes and Adjusted Gross MarginFree Cash Flow Free Cash FlowMONTREAL, Aug. 11, 2022 (GLOBE NEWSWIRE) — Rogers Sugar Inc.’s (“our,” “we”, “us” or “Rogers”) (TSX: RSI) today reported third quarter fiscal 2022 results with consolidated adjusted EBITDA of $23.1 million and $73.2 million for the current quarter and the first nine months of the year, respectively. We are announcing today our intention to proceed with an expansion...

MONTREAL, Aug. 11, 2022 (GLOBE NEWSWIRE) — Supremex Inc. (“Supremex” or the “Company”) (TSX: SXP), a leading North American manufacturer and marketer of envelopes and a growing provider of paper-based packaging solutions, today announced its results for the second quarter ended June 30, 2022. The Company will hold a conference call to discuss these results, today at 11:00 a.m. (Eastern Time). Second Quarter Financial Highlights and Recent EventsTotal revenue increased by 20.7% to $62.5 million, from $51.8 million in the second quarter of 2021. Packaging and specialty products segment revenue of $16.6 million, a slight increase of 0.4% compared to last year. Envelope segment revenue up 30.2% to $45.9 million, from $35.2 million in the prior year. Adjusted EBITDA1 of $13.9 million, or 22.3% of revenue, up from $8.6 million, or...

BEDFORD, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) — Berkshire Grey Inc. (Nasdaq: BGRY), a leader in AI-enabled robotic solutions that automate supply chain processes, today announced results for its second quarter ended June 30, 2022. Second Quarter Financial HighlightsRevenue of $23.4 million, an increase of $18.9 million or 421% as compared to the second quarter of 2021.$20 million in new orders in the second quarter of 2022 and through July 31, 2022.Backlog of $100 million, which includes orders through July 31, 2022.Net loss of $29.0 million or $(0.12) per diluted share.Adjusted EBITDA of $(30.3) million.$108 million of cash and cash equivalents with no debt as of June 30, 2022.Second Quarter and Recent Business HighlightsBerkshire Grey expanded its strategic relationship with FedEx, an existing customer. Please...

Delivers Second Quarter Year-over-Year Net Sales Growth of 14.3% Repurchased 2 Million Shares for $15 million During the Second Quarter; $85 Million Remaining Under the Existing Authorization Updates Fiscal 2022 Guidance LATHAM, N.Y., Aug. 11, 2022 (GLOBE NEWSWIRE) — Latham Group, Inc. (“Latham” or “the Company”) (Nasdaq: SWIM), the largest designer, manufacturer and marketer of in-ground residential swimming pools in North America, Australia and New Zealand, today announced financial results for the second quarter of its fiscal year 2022 ended July 2, 2022. Second Quarter Fiscal 2022 Highlights:Net sales of $206.8 million, up 14.3% year-over-year Net income of $4.3 million versus net loss of $53.6 million in the prior year period, representing a 2.1% net income margin Adjusted EBITDA of $48.7 million, up 13.5% year-over-year,...

– Following the recent submission of the IND application for CNTY-101 and pending FDA clearance, the Phase 1 ELiPSE-1 trial in relapsed/refractory lymphoma is on track to commence in the second half of 2022 – – Ended second quarter 2022 with cash, cash equivalents, and investments of $429.4; Expected cash runway into 2025 – PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) — Century Therapeutics, Inc., (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the second quarter ended June 30, 2022. “We are excited about our recent IND submission for our lead candidate, CNTY-101, and pending FDA clearance, are looking forward to initiating the Phase 1 ELiPSE-1 trial...

Advancement across Company’s pipeline towards regulatory and data milestones BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the second quarter ended June 30, 2022. The Company also shared updates across its pipeline, including its clinical stage programs, with the continued advancement of IK-930, an oral transcriptional enhanced associate domain (TEAD) inhibitor product candidate targeting the Hippo signaling pathway, and IK-175, an oral aryl hydrocarbon receptor (AHR) antagonist. “We are excited about the progress Ikena has made in the first half of 2022, especially on our IK-930 and IK-175 programs. The entire team and I are looking forward to continuing the momentum...

Better Choice Reports Record Second Quarter 2022 Gross Sales of $19.8 Million and Net Sales of $16.5 Million, Representing a Quarter-Over-Quarter Increase in Net Sales of 50%, Driven by 133% Increase in Brick & Mortar Sales and 75% Increase in International Sales. Better Choice Reports Record First Half 2022 Gross Sales of $39.5 Million and Net Sales of $33.5 million, representing a Year-Over-Year Increase in Net Sales of 54%. Better Choice Reports Second Quarter Gross Margin of 29% and Adjusted Gross Margin of 31%, Representing an Increase from First Quarter 2022 Gross Margin of 28%. Better Choice Believes Second Quarter 2022 Cash Balance of $17.8 million is Sufficient to Support Plan to Achieve Profitability and Expects Positive Changes to Net Working Capital Position in 2H 2022.NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) —...

Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023 Phase 3 VIITAL™ study topline data expected in late-3Q/early-4Q 2022 upon completion of final patient monitoring visit in mid-September Baseline wound characteristics in VIITAL™ reveal significant scope for pain reduction and EB-101 differentiation NEW YORK and CLEVELAND, Aug. 11, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced financial results for the second quarter of 2022. The Company will host a conference call and webcast today, August 11, 2022, at 8:30 a.m. ET, to discuss its financial results and business update. “We have taken decisive action to focus our resources on our lead asset EB-101, for which we expect pivotal Phase 3 VIITAL™ topline results...

NATURAL GAS SERVICES GROUP ANNOUNCES EARNINGS SCHEDULE FOR SECOND QUARTER 2022 RESULTS Midland, Aug. 11, 2022 (GLOBE NEWSWIRE) — Natural Gas Services Group, Inc. (NYSE: NGS) today announced the Company’s schedule for releasing its second quarter 2022 results for the three months ended June 30, 2022. In a press release to be issued after market close on Monday, August 15, 2022, the Company will release its second quarter 2022 financial and operating results for the three months ended June 30, 2022. The Company will host its earnings conference call on Tuesday, August 16, 2022, at 8:30AM EDT (7:30am CDT). To participate in the call, participants should access the webcast on www.ngsgi.com under the Investor Relations section. To connect telephonically, call (800) 550-9745 approximately five minutes prior to the start of the call using...

Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the NDA for VP-102 for the treatment of molluscum contagiosum Verrica has begun working with Piramal Pharma Solutions for production of bulk solution and reaffirms plans to resubmit NDA for VP-102 for molluscum contagiosum in Q1 2023 Raised approximately $28.5 million of gross proceeds in an underwritten public offering WEST CHESTER, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2022. “This quarter, we held a Type A meeting with the FDA regarding the path forward for the resubmission and potential...